The "other two" abstracts

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
biopearl123
Posts: 235
Joined: Fri Jul 20, 2018 5:13 pm

The "other two" abstracts

Post by biopearl123 » Mon Nov 18, 2019 7:57 pm

First off, thanks to recent posters, hunt and commsman, for their contributions and thoughts. I wanted to mention the "other two" ASH abstracts related to Geron but not acknowledged in the recent PR. You can read them here (in addition to the two that Geron has referenced): https://ash.confex.com/ash/2019/webprog ... 22999.html

One is a compilation of RWD studies (including the Italian study we have discussed previously) reinforcing the poor outlook in R/R MF patients. The other is from Japan and while this latter study references Imetelstat, it curiously does not mention Geron by name, unless I missed it, even to acknowledge whether it provided Imetelstat to them, which it had to since its not on the market (in contract to the Rux combo study which does not really mention Incyte but since Rux can be purchases on the open market, probably doesn't have to). Again the idea as noted by others that sequential administration of Imetelstat with other therapeutic agents (including radiation) is explored. Best Wishes to all, bp

Post Reply